|
|
|
|
|
|
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
|
MechanismH3 receptor antagonists |
Active Org.- |
|
Active Indication- |
|
Drug Highest PhaseDiscontinued |
First Approval Ctry. / Loc.- |
First Approval Date- |
|
MechanismBACE1 inhibitors |
Active Org.- |
|
Active Indication- |
|
Drug Highest PhaseDiscontinued |
First Approval Ctry. / Loc.- |
First Approval Date- |
The effect of HPP-A in the transplant model of psoriasis; in which a psoriatic lesion is induced in non-lesional skin transplanted onto immune-deficient (BNX) mice by injecting super-antigen activated peripheral blood cells intra-dermally into the transplant - The effect of HPP-A in the transplant model of psoriasis;
A 26 Week Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Safety and Efficacy of Various Doses of HPP404 on Weight Loss in Overweight or Obese Subjects
The purpose of this study is to compare the safety and effect of HPP404 versus placebo on body weight in overweight or obese subjects.
A Randomized, Double-blind, Placebo Controlled, Phase I Study to Evaluate the Safety and Tolerability of 28 Day Treatment With HPP593 Capsules in Healthy Volunteers During and After Limb Immobilization
This is a safety and tolerability study investigating the effect of HPP593 in healthy volunteers during and after limb immobilization.
100 Clinical Results associated with vTvx Holdings II LLC
0 Patents (Medical) associated with vTvx Holdings II LLC
100 Deals associated with vTvx Holdings II LLC
100 Translational Medicine associated with vTvx Holdings II LLC